Are Peptides Legal? Regulator Positions in the US, Australia, UK, and EU
The legal status of peptides depends on what the peptide is, what it is being sold for, and the jurisdiction. FDA-approved peptide medicines are legal when prescribed and dispensed through licensed channels. Compounded peptides on the FDA's safety-risk list are restricted. Some peptides marketed online are sold under "research use only" labelling. Some, like melanotan II, are the subject of public regulator warnings. This page is a regulator-sourced overview; it is not legal advice.
Legal status varies by peptide and country. FDA-approved peptide medicines are legal when prescribed. Compounded versions of FDA-flagged peptides (BPC-157, CJC-1295, ipamorelin acetate, AOD-9604) are restricted. Some peptides (Semax, Selank, Epitalon) are approved in Russia but not in the US, EU, or Australia. Melanotan II is unapproved everywhere and the subject of public warnings.
Key Takeaways
- Legal status depends on the specific peptide, the marketed use, and the jurisdiction.
- FDA-approved peptide medicines (e.g. GLP-1 receptor agonists, tesamorelin, bremelanotide) are legal when prescribed and dispensed through licensed pharmacies.
- Compounded peptides on the FDA's significant-safety-risk list are restricted: BPC-157, CJC-1295, ipamorelin acetate, AOD-9604.
- "Research use only" labelling is widely used online but does not make a peptide legal for human therapeutic use.
- WADA prohibits almost all of these peptides in competitive sport, regardless of legal status in any country.
United States: FDA position
In the US, peptides used as medicines fall under FDA jurisdiction. Approved peptide medicines (GLP-1 agonists, tesamorelin, sermorelin, bremelanotide, mecasermin, etc.) are legal when prescribed and dispensed through licensed pharmacies. The FDA has separately identified several commonly compounded peptides as substances that may present significant safety risks: BPC-157, CJC-1295, ipamorelin acetate, AOD-9604, and others. The FDA position on these limits permissible compounding under sections 503A and 503B.
"Research use only" labelling on peptide products sold online is a regulatory grey area. It does not make a peptide legal for human therapeutic use.
Australia: TGA position
In Australia, the Therapeutic Goods Administration (TGA) maintains the Australian Register of Therapeutic Goods (ARTG). Peptides used as medicines are required to be on the ARTG to be supplied for therapeutic purposes. Compounded peptides supplied outside the ARTG fall under personal-importation, prescriber compounding, or unapproved-supply rules. The TGA has issued public warnings about melanotan II and other unlicensed peptide injections.
United Kingdom: MHRA position
The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines in the UK. The MHRA has issued explicit public warnings about melanotan II, citing safety concerns and unlicensed sale. Other unapproved peptides marketed for therapeutic uses without MHRA authorisation may be in breach of medicines law depending on supply context.
European Union: EMA position
In the EU, the European Medicines Agency (EMA) reviews medicines centrally. Peptide medicines without EMA or national-agency approval are not authorised for therapeutic supply in EU member states. The EMA has approved GLP-1 receptor agonists, tesamorelin, and other peptide medicines for specific indications via EPAR.
WADA: prohibited substances in sport
Independent of national legal status, the World Anti-Doping Agency (WADA) prohibits a wide range of peptides in competitive sport. Section S2 of the prohibited list covers peptide hormones, growth factors, related substances, and mimetics, including GHRH analogues, GH secretagogues, and GLP-1 analogues used for performance enhancement. Athletes subject to WADA testing should not use peptides without consulting their anti-doping authority.
Check your full medication list in seconds
Allmeds scans the widest interaction database, so you can speak with your doctor with a clear picture.
Common Questions
BPC-157 is not FDA-approved. The FDA has identified it among compounded substances that may present significant safety risks. Compounding pharmacies face restrictions on its supply. "Research use only" labelling does not make it legal for human therapeutic use.
No. Melanotan II is not approved anywhere in the world. The UK MHRA and Australian TGA have issued explicit warnings against its sale and use. Sale through unlicensed channels may be illegal depending on jurisdiction.
The "research use only" label is widely used online. It does not authorise human therapeutic use. Depending on jurisdiction, sale of unapproved peptides for human use may be illegal regardless of the label.
WADA prohibits a wide range of peptides in competitive sport, including GLP-1 agonists used for performance, GHRH analogues, GH secretagogues, and many other peptides. National legal status and WADA status are independent.
Yes. Even legal, FDA-approved peptide medicines require a prescription and clinical supervision. For unapproved peptides, a clinician can advise on the safety, legal, and regulatory implications before any decision.
References
- U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Source.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). Source.
- UK Medicines and Healthcare products Regulatory Agency (MHRA). Melanotan: do not buy or use. Source.
- European Medicines Agency. Medicines authorised in the EU. Source.
- World Anti-Doping Agency. WADA Prohibited List. Source.